Results 191 to 200 of about 564,115 (361)

Interfacial Chemistry Behind Damage Monitoring in Glass Fiber‐Reinforced Composites: Attempts and Perspectives

open access: yesPolymer Composites, EarlyView.
Role of the modifications at the interface in glass fiber reinforced composites for damage monitoring. ABSTRACT Glass Fiber Reinforced Polymers (GFRPs) are widely used in structural applications but degrade over time due to internal damage. Structural Health Monitoring (SHM) enables early damage detection, improving reliability and reducing maintenance
Marta Colombo   +10 more
wiley   +1 more source

Improved Inverse Identification of Anisotropic Polymer Properties via FEMU and VFM With Sensitivity Analysis

open access: yesPolymer Engineering &Science, EarlyView.
Heterogeneous biaxial testing for anisotropic elastic properties identification from full displacement field. ABSTRACT The stretch‐blowing process of PET bottles induces significant anisotropy in mechanical properties due to the differential elongation of macromolecular chains.
Thanh Tung Nguyen   +3 more
wiley   +1 more source

Copolymer Synthesis of N‐Vinylacetamide and 2‐Methylene‐1,3‐Dioxepane Provides a New Degradable Polymer

open access: yesJournal of Polymer Science, Volume 63, Issue 6, Page 1306-1318, 15 March 2025.
ABSTRACT N‐vinylamides, especially noncyclic N‐vinylacetamide (NVA), have been used in various applications such as biomaterials, surfactants, and hydrogels. However, their potential to copolymerize with cyclic ketene acetal (CKA) to create degradable polymers is underexplored.
Mukmin Sapto Pamungkas   +2 more
wiley   +1 more source

Evaluating Model‐Based Extrapolation of Plasma Exposure for Long‐Acting Injectable Products: From Single‐ to Multiple‐Dose Trials

open access: yesCPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Long‐acting injectable medicinal products (LAIs) prolong drug release and thereby aim to enhance adherence and patient outcomes. European regulatory guidelines require the conduct of single‐ and multiple‐dose trials to exclude differences in drug release between non‐steady and steady state conditions. The complexity of these trials may however
D. Esther Lubberts   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy